Susan G Sherman1, Kristin E Schneider2, Ju Nyeong Park3, Sean T Allen4, Derrick Hunt5, C Patrick Chaulk6, Brian W Weir7. 1. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD, 21205, USA. Electronic address: ssherman@jhsph.edu. 2. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD 21205, USA. Electronic address: kschne18@jhu.edu. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD 21205, USA. Electronic address: ju.park@jhu.edu. 4. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD, 21205, USA. Electronic address: sallen63@jhu.edu. 5. Baltimore City Health Department, 1001 East Fayette St, Baltimore, MD, 21202, USA. Electronic address: derrick.hunt@baltimorecity.gov. 6. Baltimore City Health Department, 1001 East Fayette St, Baltimore, MD, 21202, USA. Electronic address: patrick.chaulk@baltimorecity.gov. 7. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD, 21205, USA. Electronic address: bweir3@jhu.edu.
Abstract
BACKGROUND: Limited research has examined pre-exposure prophylaxis (PrEP) interest among people who inject drugs (PWID). To date, few studies have examined the relationship between PrEP eligibility and PrEP interest among PWID. METHODS: Data were from an anonymous, cross-sectional survey of Baltimore Syringe Services Program (SSP) clients and non-client peers, restricted to HIV-uninfected participants (N = 265). Participants were classified as PrEP eligible/ineligible based on injection related criteria outlined in the CDC's PrEP guidelines. Participants were asked if they were previously aware of PrEP, would be interested in taking PrEP, and the ease of taking PrEP daily. Participants self-reported their sociodemographic characteristics, health diagnoses, and recent drug use, overdose, and drug treatment history. We estimated bivariate and multivariate logistic regression models to test for significant predictors of interest in PrEP. RESULTS: One-quarter of PWID had previously heard of PrEP and 63% of the sample was interested in taking PrEP. Only two respondents were currently taking PrEP. The majority (89%) thought taking PrEP every day would be easy. In the presence of other variables, PrEP interest was associated with PrEP eligibility (adjusted odds ratio [aOR] = 2.46; 95% Confidence Interval [CI]:1.34,4.50) and the number of medical diagnoses (aOR = 1.16; 95% CI:1.01,1.33) CONCLUSIONS: Most PWID were unaware of PrEP but interested in taking it. PWID who were eligible for PrEP are more likely to be interested in taking it. Having co-morbid conditions was an important correlate of PrEP interest. These results underscore the importance of providers across the healthcare sector engaging PWID in discussions about PrEP.
BACKGROUND: Limited research has examined pre-exposure prophylaxis (PrEP) interest among people who inject drugs (PWID). To date, few studies have examined the relationship between PrEP eligibility and PrEP interest among PWID. METHODS: Data were from an anonymous, cross-sectional survey of Baltimore Syringe Services Program (SSP) clients and non-client peers, restricted to HIV-uninfectedparticipants (N = 265). Participants were classified as PrEP eligible/ineligible based on injection related criteria outlined in the CDC's PrEP guidelines. Participants were asked if they were previously aware of PrEP, would be interested in taking PrEP, and the ease of taking PrEP daily. Participants self-reported their sociodemographic characteristics, health diagnoses, and recent drug use, overdose, and drug treatment history. We estimated bivariate and multivariate logistic regression models to test for significant predictors of interest in PrEP. RESULTS: One-quarter of PWID had previously heard of PrEP and 63% of the sample was interested in taking PrEP. Only two respondents were currently taking PrEP. The majority (89%) thought taking PrEP every day would be easy. In the presence of other variables, PrEP interest was associated with PrEP eligibility (adjusted odds ratio [aOR] = 2.46; 95% Confidence Interval [CI]:1.34,4.50) and the number of medical diagnoses (aOR = 1.16; 95% CI:1.01,1.33) CONCLUSIONS: Most PWID were unaware of PrEP but interested in taking it. PWID who were eligible for PrEP are more likely to be interested in taking it. Having co-morbid conditions was an important correlate of PrEP interest. These results underscore the importance of providers across the healthcare sector engaging PWID in discussions about PrEP.
Authors: Bradley M Mathers; Louisa Degenhardt; Benjamin Phillips; Lucas Wiessing; Matthew Hickman; Steffanie A Strathdee; Alex Wodak; Samiran Panda; Mark Tyndall; Abdalla Toufik; Richard P Mattick Journal: Lancet Date: 2008-09-23 Impact factor: 79.321
Authors: Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Holly Hagan; David C Perlman; Salaam Semaan Journal: Am J Public Health Date: 2011-05-12 Impact factor: 9.308
Authors: Roman Shrestha; Pramila Karki; Frederick L Altice; Tania B Huedo-Medina; Jaimie P Meyer; Lynn Madden; Michael Copenhaver Journal: Drug Alcohol Depend Date: 2017-02-02 Impact factor: 4.492
Authors: Michelle M Van Handel; Charles E Rose; Elaine J Hallisey; Jessica L Kolling; Jon E Zibbell; Brian Lewis; Michele K Bohm; Christopher M Jones; Barry E Flanagan; Azfar-E-Alam Siddiqi; Kashif Iqbal; Andrew L Dent; Jonathan H Mermin; Eugene McCray; John W Ward; John T Brooks Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Andreas B Eisingerich; Ana Wheelock; Gabriela B Gomez; Geoffrey P Garnett; Mark R Dybul; Peter K Piot Journal: PLoS One Date: 2012-01-11 Impact factor: 3.240
Authors: Kristin E Schneider; Ju Nyeong Park; Sean T Allen; Brian W Weir; Susan G Sherman Journal: Drug Alcohol Depend Date: 2019-06-06 Impact factor: 4.492
Authors: Sean T Allen; Allison O'Rourke; Rebecca Hamilton White; Katherine C Smith; Brian Weir; Gregory M Lucas; Susan G Sherman; Suzanne M Grieb Journal: AIDS Behav Date: 2020-06
Authors: Kristin E Schneider; Rebecca Hamilton White; Rashelle J Musci; Allison O'Rourke; Michael E Kilkenny; Susan G Sherman; Sean T Allen Journal: J Stud Alcohol Drugs Date: 2020-11 Impact factor: 2.582
Authors: Marcelo H Fernández-Viña; Nadya E Prood; Adam Herpolsheimer; Joshua Waimberg; Scott Burris Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Suzan M Walters; Bethany Coston; Alan Neaigus; Alexis V Rivera; Lila Starbuck; Valentina Ramirez; Kathleen H Reilly; Sarah L Braunstein Journal: Int J Drug Policy Date: 2020-02-21
Authors: Kristin E Schneider; Ju Nyeong Park; Sean T Allen; Brian W Weir; Susan G Sherman Journal: Public Health Rep Date: 2020-04-07 Impact factor: 2.792
Authors: Suzan M Walters; Alex H Kral; Kelsey A Simpson; Lynn Wenger; Ricky N Bluthenthal Journal: Subst Use Misuse Date: 2020-09-23 Impact factor: 2.164